Angiotensin Converting Enzyme 2 News and Research

RSS

Yeast display used to generate SARS-CoV-2 RBD-specific nanobodies

Researchers engineered biparatopic nanobodies against SARS-CoV-2.

5 Oct 2022

Novel protein vaccine NVX-CoV2373 triggered functional T cell responses to SARS-CoV-2

Researchers determined the T cell response to the NVX-CoV2373, an adjuvanted recombinant full-length SARS-CoV-2 spike (S) trimer protein vaccine.

5 Oct 2022

Study shows SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells

Researchers demonstrated infection of human adipose tissue by SARS-CoV-2.

5 Oct 2022

Omicron reduces host antibody response by lower B-cell antigenicity

A new study explores the functional relevance of some Omicron mutations in terms of their ability to escape neutralizing antibody responses.

4 Oct 2022

What are the challenges of COVID-19 vaccination and herd immunity?

A new study reviewed the challenges of coronavirus disease 2019 (COVID-19) vaccination and herd immunity.

4 Oct 2022

How COVID-19 affects the female reproductive system

A new review in the Biology of Reproduction journal analyzed the relationship between the immune system and the female reproductive system while focusing on the effects of COVID-19-associated immune responses on the reproductive system. The study searched PubMed to identify peer-reviewed literature in English up to May 2022 and finally included 83 studies.

3 Oct 2022

Researchers report aminoadamantanes that block SARS-CoV-2 infection by S-nitrosylation of the host ACE2 protein

Researchers investigated the use of aminoadamantane nitrate compounds as anti-SARS-CoV-2 drugs.

3 Oct 2022

Novel linear DNA SARS-CoV-2 vaccine using electroporation-aided vaccine delivery reveals lower viral shedding in ferrets

Researchers evaluated the efficacy, immunogenicity, and safety of a novel SARS-CoV-2 linear deoxyribonucleic acid vaccine in ferret models delivered using intramuscular injection and electroporation.

3 Oct 2022

Broadly neutralizing antibodies are the blueprint for variant-proof, pansarbecovirus vaccines

A recent Nature Reviews Immunology study has summarized the efficacy of neutralizing antibodies that target four main regions of the spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), namely, the receptor-binding domain (RBD) in the S1 subunit, the fusion peptide region in the S2 subunit, the stem helix region, and the N-terminal domain.

2 Oct 2022

SARS-CoV-2 spike protein and messenger ribonucleic acid found to translocate into the nucleus

In a new study, researchers reported severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) spike (S) protein and S messenger ribonucleic acid (mRNA) nuclear co-translocation as a novel feature of SARS-CoV-2 pathogenesis.

30 Sep 2022

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

A new study demonstrated the efficacy of a newly engineered angiotensin-converting enzyme 2 (ACE2) based immunoadhesin against Omicron and other SARS-CoV-2 VOCs.

30 Sep 2022

Bioactive compounds derived from Ganoderma lucidum exhibit anti-SARS-CoV-2 activity

Scientists have identified lucidenic acid A, one of the bioactive compounds of Ganoderma lucidum, as a potential inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) host cell entry. The study has recently been published in the journal Food and Chemical Toxicology.

29 Sep 2022

A novel method to identify spike stabilizing mutations for COVID-19 vaccine development

Researchers discuss a robust method to identify mutations that improve the expression and stabilize the conformation of the SARS-CoV-2 spike protein.

29 Sep 2022

Duration of infectiousness, predictors of ongoing individual infectiousness, and diagnostic tests for acute SARS-CoV-2 infection

Researchers explored SARS-CoV-2 variants of concern/interest (VOC/VOI) kinetics and variations among non-hospitalized acute COVID-19 patients.

29 Sep 2022

What is the role of N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 spike maturation?

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products

Researchers comparatively evaluated antibody responses against SARS-CoV-2 among immunodeficient individuals pre- and post-intravenous immunoglobulin product infusions.

27 Sep 2022

Angiotensin Converting Enzyme 2 News and Research

Yeast display used to generate SARS-CoV-2 RBD-specific nanobodies

Novel protein vaccine NVX-CoV2373 triggered functional T cell responses to SARS-CoV-2

Study shows SARS-CoV-2 infects human adipose tissue and undergoes productive infection in fat cells

Omicron reduces host antibody response by lower B-cell antigenicity

What are the challenges of COVID-19 vaccination and herd immunity?

How COVID-19 affects the female reproductive system

Researchers report aminoadamantanes that block SARS-CoV-2 infection by S-nitrosylation of the host ACE2 protein

Novel linear DNA SARS-CoV-2 vaccine using electroporation-aided vaccine delivery reveals lower viral shedding in ferrets

Broadly neutralizing antibodies are the blueprint for variant-proof, pansarbecovirus vaccines

SARS-CoV-2 spike protein and messenger ribonucleic acid found to translocate into the nucleus

Effectiveness of anti-SARS-CoV-2 immunoadhesin against omicron and other emerging variants

Bioactive compounds derived from Ganoderma lucidum exhibit anti-SARS-CoV-2 activity

A novel method to identify spike stabilizing mutations for COVID-19 vaccine development

Duration of infectiousness, predictors of ongoing individual infectiousness, and diagnostic tests for acute SARS-CoV-2 infection

What is the role of N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 spike maturation?

Can the gut be an alternative route for SARS-CoV-2 entry?

How the gut microbiome could affect COVID-19 severity

Italian scientists investigate whether stranded cetaceans show evidence of SARS-CoV-2 infection

Association of self-reported chronic fatigue and retinal microcirculation in post-COVID-19 syndrome patients

The antibody response against SARS-CoV-2 in patients pre- and post-infusion with commercial intravenous immunoglobulin products

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News